ƒ ‹ F | Œfia‹ ˙'e›ß• |–M^D‹ ª¤s›p e ƒ¤"G‡ł§i

, ¡‰⁄›Ø´ ‡Nƒb›G ø¤ , ¡‰⁄´ † "v ł⁄W' §Œ"t""¤⁄ƒ (II)

›p e^ §¡G §O«‹ ›p e

›p e‰ ¸„¡GNSC92-2314-B-038-046-

ıƒ · ¶¡¡G92 ƒ~08 ⁄°01 ⁄ Ø 93 ƒ~07 ⁄°31 ⁄Ø

ıƒ ‡ ƒ ¡G» O ¥´ ˙⁄j ˙´ ˙¤t

›p e¥ D ø⁄¡HG` ´ Z§

ƒ ¶P¥ D ø⁄¡HG§ d ‹⁄

›p e »P⁄H›ß¡GYutaka Yonemura

‡ł§i^ «‹¡G" °†‡ł§i

‡ B † zŁ¡fG¡¥»›p e¥ i ⁄ ‰ ¶‹ d,

⁄⁄ ¥` Œ 93 ƒ~12 ⁄°14 ⁄Ø

ƒ ‹ F | Œfia‹ ˙'e›ß• |, §U–M^D‹ ª¤s›p eƒ¤"G‡ł§i

¡ ¡

¡ , ¡‰/›Ø´ ‡Nƒb›G ø¤ , ¡‰/´ † "v ł/W' §Œ"t""¤/ƒ ¡

¡ – †˜/Gƒ~›p e ¡

¡ **The role of peritonectomy in treatment of gastric** ¡

¡ **cancer with peritoneal dissemination - the second** ¡

¡ **year protocol** ¡

¡ ¡

›p e^ § O ¡ G ‰ ››p§Œ«‹ ¡ … ƒX«¤ e

›p e‰ s „ ¡NSC92¡–2314¡–B¡–038¡–0 ¡–

ı ƒ ˙¶¡ ¡92 ƒ~ 8 /° 1 / Ø 93 ƒ~ 7 /° 31 /Ø

› p e ¥ D « ø H¡G` ´›Z§

ƒ @ ƒ P ¥ D « ø / H¡G¥ ¡Yutaka Yonemura

¥ » ƒ ¤ " G ‡ ł § i ¥] ‹ A H/¡G ‡^"¥ /§" ¥
¡ ‰ › u Œ ¥ ~ ¥ X fi t ' ¸ ‹ª† / –o‡ł§i/@¥
¡…›u/ j ‡ ƒa¥ X fi t ' ¸ ‹ ª † /–o‡ł§i/@¥
¡…¥Xfiu Œ› ˙ N•/| ˜‡– ‡ł§i¸ o"/§‰ /ƒU ¥
¡… Œ› X§‹@ª¤ s p e Œ ¥‹¤s‡ §ifi / ¥

ƒ ‡ ƒ ¡G¥ x ¥ _ ´ ˙ j ˙´ ˙¤t

// ¥` Œ 93 ƒ~ 7 /° 31 /Ø

, ¡‰⁄›Ø´ †Nfb›G ø¤ , ¡‰⁄´ † "v ±⁄W' S Œ"t""¤⁄ƒ - †˜⁄Gƒ~›p e

The role of peritonectomy in treatment of gastric cancer with peritoneal dissemination - the second year protocol

›p e‰ s „¡NSC92-2314-B038-0

ı ƒ ` ›92¡fG8⁄°1⁄Ø ƒ 93ƒ~7⁄°31⁄Ø

¥ D « ø ⁄ H ¡ G ` ´ › Z S ¡ A ¥¥_´ ·⁄j ·´ ·¤t

ƒ @ ƒ P ¥ D « ø ⁄ H ¡ G S d ‹ ⁄¡A¥x¥_"a¥``'´ |

ƒ @ ƒ P ¥ RøŸuHtaGa Yonemura¡A

Shizuoka Cancer Center, Japan

⁄@¡B⁄⁄ "K›n

¥»ƒ~« U¥fb~ ‰ ^ ¥ ´ p†q" ¥›T¡B‰t¥

‹ ¤s›p e⁄ £ ¥ ¡g⁄„HL Ø , ¯…¡fAf]

ƒ „ Œ»›p e⁄S ƒ ¥ u ' ⁄U¥k« ¶}

'l¡A¥ «'¥x˘ W ⁄ w ¥] ‹ ¥|¤Affl f¤

' ⁄Ø¥ » R'fœflf⁄⁄ ´ |⁄] ⁄ ¥]‹A

¥ | ¤ flf¤A« « H ¥ … ¤ • ƒ†S ƒh⁄Sflf

¤ ¡Af '⁄U@f~« N S@`⁄⁄ ¸ Q¸⁄

" R C

⁄G¡B›^⁄ "K›n

We were informed that this study could be performed purely for surgical procedure clinical trial, so that the formal study was began in the later half year. There are four cases enrolled in this study in Taiwan, and there are also four cases enrolled in Shizuoka Cancer Center Hospital. We believe that there will be more cases enrolled in the next year and mid term analysis will be perform in the next year.

› G ø ƒ X ¤ ƒ † , ¡ ˜⁄",¡‰⁄´ † ¡A

⁄ @ fl ° ± ‹ ¥ ‰ · ` " ‹ Þƒ ⁄£ „⁄'¿n•¥"v

± ¡ A ¤ ⁄ › ƒ ~ ƒ‹<¬5ª‰Y•¥S¢›¡†]

S U ' ° ⁄ ` £ " " † " G ß⁄£⁄` £"" †"G‹

¤ ¸¡ C ⁄ @ fl ° „ ' ƒ „ ^ flf–w‹ „⁄'¥ ¤›

" " ⁄ ˘ · ± " k ¡ A ƒ fi "G⁄£¤¸¡C,¡ ˜⁄"

· " v ± " " † " G ‹ O ⁄ @ ¥iƒ ""†~fi|¡A

¤ › › ' ƒ U " ƒ] fl ¡ A]ƒ„¥ufl ‹Iƒ '

† N ⁄ ⁄ " " , ¡ ˜ ⁄ " ⁄ ˘ "v ±¡C›Y' ⁄ †N

‹ I ƒ , ¡ ˜ ⁄ " " " • ¯ … ⁄˘ ·"v ±¡A«e´⁄

" " ‹ ª ¤ s ¯ ª ¥ † " G ¥ ,ßƒn¡Cƒ ‹O„ '

⁄ j " " ´ † fl f ¤ _ ¡ A ¥⁄£¥H⁄ †N⁄±ƒ¡⁄`

£ ¡ A « h , ¡ ˜ ⁄ " " " • … ⁄˘ ·"v ± †"G

⁄ £ ƒ n ¡ C , ¡ ‰ ⁄ › Ø ´ † NK‹O w„ ƒ„" "‹

ƒ o fi i ¥ X ¤ " " ¡ A ¤ ƒb⁄j,z ø"""v ±

" G ` M ¥ O ⁄ H fi ¶ ˜ ¡ AMƒ «o¥…ƒ†›G ø

– w " " « e ´ ⁄ '""‹ ª¤s¡C

¥|¡B S fi˘⁄¸⁄±"k

„ ' ›G¤ƒ† , ¡ ˜ ⁄ " † ""flf

[illegible] MMC 30 mg; cisplatin 150 mg; etoposide 100 mg; [illegible] Taxotere 20 mg/body /day; [illegible] 5-FU 650 mg/m^2/day; [illegible] MMC 10 mg /m^2 – D1; etoposide 60 mg -- D3-5; [illegible]

[illegible]

[illegible]

[illegible]

1. Dedrick RL, Myers CE, Bungay PM, DeVita VT. Pharmacokinetic rational for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep 1978; 62:1-9.
2. Lukas G, Brindle SD, Greengard P. The route of absorption of intraperitoneally administered compounds. Pharmacol Exp Ther 1971; 178:562-566.
3. Torres IL, Litterst CL, Guarino AM. Transport of model compounds across the peritoneal membrane in the rat. Pharmacology 1978; 17:330-340.
4. Sugarbaker PH, Stuart OA, Vidal-Jove J, Pessagno AM, DeBruijn EA. Studies of the peritoneal plasma barrier after systemic mitomycin C administration. Reg Cancer Treat 1993; 4:188-194.
5. Markman M. Intraperitoneal chemotherapy. Sem Oncol 1991; 18: 248-254.
6. Sugarbaker PH. Indications. (In) Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. Manual for physicians and nurses. Michigan, The Ludann Company Grand Rapids, 3rd Ed., 1998: 6-8.
7. Fujimoto S, Takahashi M, Kobayashi K, et al. Relation between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for patients with gastric cancer

and peritoneal metastasis. Oncology 1993; 50: 338-343.

8. van der Vaart PJM, van der Vange N, Zoetmulder FAN, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34: 148-154.
9. Ozols RF, Locker GY, Doroshow JH, et al. Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer. Cancer Res 1979; 39:3209-3214.
10. McVie JG, Dikhoff T, van der Heide J, et al. Tissue concentration of platinum after intraperitoneal cisplatinum administration in patients. Proc Am Assoc Cancer Res 1985; 26: 162.
11. Jacquet P, Averbach AM, Stephens AD, Stuart OA, Chang D, Sugarbaker PH. Heated intraoperative intraperitoneal mitomycin C and early postoperative intraperitoneal 5-fluorouracil: Pharmacokinetic studies. Oncology 1998; 55(2):130-138.
12. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Dis Colon Rectum 1994; 37(Suppl): S115-S122.
13. Sugarbaker PH. Managements of peritoneal surface malignancy: the surgeon's role. Langenbeck's Arch Surg 1999; 384: 576-587.
14. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol 1998; 14: 254-261.
15. Sugarbaker PH. Peritonectomy procedures. Ann Surg 1995; 221: 29-42.
16. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer. Randomized controlled study. World J Surg 1994; 18: 150-155.
17. Fujimura T, Yonemura Y, Kawamura T, et al. Cytoreductive surgery and sandwich therapy with chemo-hyperthermic peritoneal perfusion and intra-aortic chemotherapy for peritoneal dissemination in gastric cancer. Oncol Rep 1996; 3: 513-517.
18. Fujimura T, Yonemura Y, Nakagawara H, et al. Subtotal peritonectomy with chemohyperthermic peritoneal perfusion for peritonitis carcinomatosa in gastrointestinal cancer. Oncol Rep 2000; 7(4): 809-814.
19. Hsieh MC, Wu CW, Lo SS, et al. Short term results of peritonectomy with intraperitoneal hyperthermochemotherapy for gastric cancer patients with peritoneal carcinomatosis. (Free paper) presented at the General Scientific Meeting of Surgical Association (56th), ROC, Taipei, March 1997.
20. Hsieh MC, Wu CW, Lo SS, et al. Peritonectomy with intraperitoneal hyperthermochemotherapy versus intraperitoneal hyperthermochemotherapy for peritoneal carcinomatosis in gastric cancer patients. (Free paper) presented at

the 2nd International Gastric Cancer Conference, Munichen, German, April 1997.

21. Yonemura Y, Aretxabala X, Fujimura T, et al. Intraoperative chemo-hyperhermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study. Hepato-Gastroenterol 2001; 48: 1776-1782.
22. Fujimura T, Yonemura Y, Muraoka K, et al. Continuous hyperthermic peritoneal perfusion for the prevention of peritoneal recurrence of gastric cancer: randomized controlled study. World J Surg 1994; 18: 150-155.
23. Japanese Research Society of Gastric Cancer (JRSGC). Japanese classification of gastric carcinoma. Kanehara & Co., Ltd., Tokyo, 1995.
24. Japanese Research Society of Gastric Cancer. The general rules for the gastric cancer study in surgery and pathology. Jpn J Surg 1981; 11: 127.
25. UICC International Union Against Cancer. TNM classification of malignant tumours. Springer-Verlag London, 1997, 4th Ed.
26. Sugarbaker PH. Indications. (In) Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. Manual for physicians and nurses. Michigan, The Ludann Company Grand Rapids, 3rd Ed., 1998: 13-20.
27. Yonemura Y. Surgical techniques for radical gastrectomy and procedures for intraoperative hyperthermo-chemotherapy. In: Contemporary approaches toward cure of gastric cancer. Maeda Shoten Co., Ltd. 1996; 139-180.
28. [illegible]
29. Ouchi K, Sugawara T, Ono H, et al. Therapeutic significance of palliative operations for gastric cancer for survival and quality of life. J Surg Oncol 1998; 69: 41-44.
30. Kakeji Y, Maehara Y, Tomoda M, et al. Long term survival of patients with stage IV gastric carcinoma. Cancer 1998; 82: 2307-2311.
31. [illegible]
32. Woolson RF. Estimation and comparison of survival curves. In: Statistical methods for the analysis of biomedical data. P442–464, New York 1987, John Wiley & Sons, Inc.
33. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.
34. Cox, DR. Regression models with life tables. J Royal Stat Society, Serie B 1972; 34: 187–220.
35. [illegible]

[Schema]


Adenocarcinoma of the Stomach
Registration (Sign Informed Consent)
Laparotomy ➔➔➔ not illegible ➔➔➔ excluded and illegible
Randomization
D2 Gastrectomy
Subtotal Peritonectomy
HIIC
EPIC
D2 Gastrectomy

HIIC
EPIC
Adjuvant Chemotherapy
Adjuvant Chemotherapy
Follow Up
Follow Up